Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | November 08, 2021 | November 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date November 08, 2021 · Filed November 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,932 |
Last balance in matching sequence
After 2021-11-08 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2021-11-08 · Exercise / conversion · Acquired 22,302 · Balance 51,234 F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Row 2 · 2021-11-08 · Sale · Disposed 22,302 · Balance 28,932 F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Row 3 · 2021-11-08 · Exercise / conversion · Acquired 4,166 · Balance 33,098 F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Row 4 · 2021-11-08 · Sale · Disposed 4,166 · Balance 28,932 F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.02 · Expires 2023-01-02 | Direct | 0 |
Reported balance
After 2021-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-08 · Exercise / conversion · Disposed 22,302 · Balance 0 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.46 · Expires 2022-05-22 | Direct | 0 |
Reported balance
After 2021-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-08 · Exercise / conversion · Disposed 4,166 · Balance 0 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse | 1,850 |
Reported balance
Holding disclosure · report date 2021-11-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,850 |
Filing footnotes · ownership attribution and instrument terms
F1: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
TETRAPHASE PHARMACEUTICALS INC
Report date July 28, 2020 · Filed July 29, 2020
Section 16 reporting ended · disclosed 2020-07-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-07-28 transaction · row 1
1 source rowRow 1 · 2020-07-28 · Other · Disposed 1,944 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) $2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 0 |
Reported balance
After 2020-07-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-07-28 · Other · Disposed 191 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) $2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) $2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 08, 2021 Filed Nov 8, 2021 22:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,166 | $0.00 Strike: $5.46 | $0.00 |
DisclosureSEC source: 0001061983-21-000253 · edgardoc.xml · derivative · entry 7 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,166 shares Expires 2022-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 22:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 22,302 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001061983-21-000253 · edgardoc.xml · derivative · entry 6 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,302 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 22:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 4,166 | $41.33 | $172,196.61 |
DisclosureSEC source: 0001061983-21-000253 · edgardoc.xml · nonDerivative · entry 4 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,932 F1 · balance_after: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 22:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 4,166 | $5.46 | $22,746.36 |
DisclosureSEC source: 0001061983-21-000253 · edgardoc.xml · nonDerivative · entry 3 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 22:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 22,302 | $41.33 | $921,826.41 |
DisclosureSEC source: 0001061983-21-000253 · edgardoc.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,932 F1 · balance_after: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| November 08, 2021 Filed Nov 8, 2021 22:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 22,302 | $4.02 | $89,654.04 |
DisclosureSEC source: 0001061983-21-000253 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 23:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 510 | $36.74 | $18,737.40 |
DisclosureSEC source: 0001061983-21-000228 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,932 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $36.74, representing the Issuer's closing stock price on October 1, 2021. F2 · balance_after: Amount includes 3,128 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 893 | $20.98 | $18,735.14 |
DisclosureSEC source: 0001061983-21-000173 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,422 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $20.98, representing the Issuer's closing stock price on July 1, 2021. F2 · balance_after: Amount includes 2,618 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.32 | $0.00 |
DisclosureSEC source: 0001061983-21-000139 · edgardoc.xml · derivative · entry 3 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-12 F3 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/12/2021 and the last such installment vesting on 05/12/2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-21-000139 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,529 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/12/2022. F2 · balance_after: Amount includes 1,725 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 767 | $24.44 | $18,745.48 |
DisclosureSEC source: 0001061983-21-000097 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,529 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $24.44, representing the Issuer's closing stock price on April 1, 2021. F2 · balance_after: Amount includes 1,725 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 22:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001061983-21-000085 · edgardoc.xml · derivative · entry 4 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 22:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 10,000 | $24.45 | $244,468.00 |
DisclosureSEC source: 0001061983-21-000085 · edgardoc.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,762 Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 22:55 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 10,000 | $5.88 | $58,800.00 |
DisclosureSEC source: 0001061983-21-000085 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 12, 2021 23:58 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,333 | $0.00 Strike: $8.64 | $0.00 |
DisclosureSEC source: 0001061983-21-000083 · edgardoc.xml · derivative · entry 7 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 12, 2021 23:58 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,006 | $0.00 Strike: $5.88 | $0.00 |
DisclosureSEC source: 0001061983-21-000083 · edgardoc.xml · derivative · entry 6 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 7,006 shares Expires 2022-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 12, 2021 23:58 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 3,333 | $21.22 | $70,719.26 |
DisclosureSEC source: 0001061983-21-000083 · edgardoc.xml · nonDerivative · entry 4 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,762 Read SEC document |
| March 12, 2021 Filed Mar 12, 2021 23:58 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,333 | $8.64 | $28,797.12 |
DisclosureSEC source: 0001061983-21-000083 · edgardoc.xml · nonDerivative · entry 3 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 12, 2021 23:58 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,006 | $21.22 | $148,652.61 |
DisclosureSEC source: 0001061983-21-000083 · edgardoc.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,762 Read SEC document |
| March 12, 2021 Filed Mar 12, 2021 23:58 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 7,006 | $5.88 | $41,195.28 |
DisclosureSEC source: 0001061983-21-000083 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 958 | $19.56 | $18,738.48 |
DisclosureSEC source: 0001061983-21-000013 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,762 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021. F2 · balance_after: Amount includes 958 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 15, 2020 Filed Dec 15, 2020 23:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,716 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001061983-20-000187 · edgardoc.xml · derivative · entry 4 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,716 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 15, 2020 23:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 7,716 | $21.00 | $162,038.31 |
DisclosureSEC source: 0001061983-20-000187 · edgardoc.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,804 Read SEC document |
| December 15, 2020 Filed Dec 15, 2020 23:09 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 7,716 | $12.96 | $99,999.36 |
DisclosureSEC source: 0001061983-20-000187 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:14 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | OtherCommon Stock | 191 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-020623 · doc4.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) $2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones. Read SEC document |
| July 28, 2020 Filed Jul 29, 2020 16:14 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | OtherCommon Stock | 1,944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-020623 · doc4.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger, dated as of June 24, 2020, by and among Tetraphase Pharmaceuticals, Inc., TTP Merger Sub, Inc. and La Jolla Pharmaceutical Company (the "Merger Agreement"), these shares were tendered and disposed of at the Acceptance Time (all terms capitalized but not defined shall have the meaning given to them in the Merger Agreement) in exchange for the right to receive (i) $2.00 per Share (the "Cash Consideration"), to the holder in cash, without interest and less any applicable withholding taxes, plus (ii) one non-transferable contractual contingent value right per Share (a "CVR") representing the right to receive certain consideration based on the achievement of net sales milestones. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 3,333 | $22.22 Strike: $16.86 | $74,059.26 |
DisclosureSEC source: 0001061983-20-000099 · edgardoc.xml · derivative · entry 4 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires 2020-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 2,529 | $22.22 | $56,194.38 |
DisclosureSEC source: 0001061983-20-000099 · edgardoc.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,804 F1 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 804 shares of Common Stock on the net exercise of a stock option to purchase 3,333 shares of Common Stock. The Issuer withheld 2,529 shares of Common Stock underlying the stock option for payment of the exercise price using a stock price on May 18, 2020 of $22.22. Read SEC document |
| May 18, 2020 Filed May 20, 2020 21:04 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 3,333 | $16.86 | $56,194.38 |
DisclosureSEC source: 0001061983-20-000099 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2020 Filed May 14, 2020 20:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $21.61 Strike: $21.61 | $432,200.00 |
DisclosureSEC source: 0001061983-20-000088 · edgardoc.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-13 F1 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments as from the date of the grant. Read SEC document |
| March 06, 2020 Filed Mar 20, 2020 19:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 8,000 | $14.82 | $118,592.00 |
DisclosureSEC source: 0001061983-20-000069 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 19:19 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantStock option (right to buy) · Derivative | 16,500 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001209191-19-036259 · doc4.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2029-06-09 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document |
| May 22, 2019 Filed Mar 20, 2020 19:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-20-000068 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · kind: Bona Fide Gift Read SEC document |
| May 15, 2019 Filed May 17, 2019 21:07 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $10.68 Strike: $10.68 | $213,600.00 |
DisclosureSEC source: 0001061983-19-000035 · edgardoc.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-15 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 15, 2020 Read SEC document |
| May 30, 2018 Filed Jun 1, 2018 16:15 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001209191-18-034658 · doc4.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-29 F1 · derivative.exercise_date: Vests in equal quarterly installments over a one-year period measured from the date of grant. Read SEC document |
| May 16, 2018 Filed May 17, 2018 22:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $9.45 Strike: $9.45 | $189,000.00 |
DisclosureSEC source: 0001061983-18-000026 · edgardoc.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal monthly installments and shall become fully vested on May 16, 2019 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 23:35 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 21,428 | $3.50 Strike: $8.75 | $75,002.29 |
DisclosureSEC source: 0001061983-18-000001 · edgardoc.xml · derivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,428 Underlying: Common Stock · 21,428 shares Expires 2028-01-02 F2 · price: This option was issued to the reporting person pursuant to the Cytokinetics 2004 Equity Incentive Plan in lieu of an annual retainer of $75,000.00. F1 · derivative.exercise_date: This option shall vest and become exercisable as to 21,428 shares divided into equal monthly installments such that the option shall be 100% vested on January 2, 2019. Read SEC document |
| November 29, 2017 Filed Dec 4, 2017 09:02 UTC | TETRAPHASE PHARMACEUTICALS INC TTPH · Entity 147285 | PurchaseCommon Stock | 3,880 | $6.45 | $25,026.00 |
DisclosureSEC source: 0001209191-17-063360 · doc4.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,880 Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001061983-17-000059 · edgardoc.xml · derivative · entry 9 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,302 Underlying: Common Stock · 5,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $14.68 | $5,870.00 |
DisclosureSEC source: 0001061983-17-000059 · edgardoc.xml · nonDerivative · entry 7 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,490 | $14.65 | $36,478.50 |
DisclosureSEC source: 0001061983-17-000059 · edgardoc.xml · nonDerivative · entry 6 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,400 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 300 | $14.60 | $4,380.00 |
DisclosureSEC source: 0001061983-17-000059 · edgardoc.xml · nonDerivative · entry 5 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,890 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 810 | $14.55 | $11,785.50 |
DisclosureSEC source: 0001061983-17-000059 · edgardoc.xml · nonDerivative · entry 4 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,190 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 600 | $14.45 | $8,670.00 |
DisclosureSEC source: 0001061983-17-000059 · edgardoc.xml · nonDerivative · entry 3 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $14.40 | $5,760.00 |
DisclosureSEC source: 0001061983-17-000059 · edgardoc.xml · nonDerivative · entry 2 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,600 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 22:53 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 5,000 | $4.02 | $20,100.00 |
DisclosureSEC source: 0001061983-17-000059 · edgardoc.xml · nonDerivative · entry 1 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · derivative · entry 11 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,302 Underlying: Common Stock · 5,000 shares Expires 2023-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $14.90 | $5,960.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 9 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 700 | $14.85 | $10,395.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 8 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,400 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 23:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 500 | $14.75 | $7,375.00 |
DisclosureSEC source: 0001061983-17-000055 · edgardoc.xml · nonDerivative · entry 7 GAGE L PATRICK · CIK 0001196903 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 F2 · kind: The sale(s) reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 8, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.